Innovent TABOSUN Becomes China's First Approved Domestic Anti CTLA 4 Antibody
Innovent Biologics has received approval from China’s National Medical Products Administration (NMPA) for TABOSUN (Ipilimumab N01 Injection), marking the country’s first domestically developed anti-CTLA-4 monoclonal antibody and a significant milestone in China’s immuno-oncology landscape.
National Medical Products Administration | 26/12/2025 | By News Bureau
WestGene Secures Dual IND Approvals for EB Virus-Related mRNA Therapeutic Cancer Vaccine
WestGene Biopharma has announced that its mRNA therapeutic cancer vaccine, WGc-043, has received dual IND approvals from China's National Medical Products Administration (NMPA) and the US FDA.
National Medical Products Administration | 09/08/2024 | By Aishwarya | 370
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy